News and Analysis | Published:

Companies hope for kinase inhibitor JAKpot

Nature Reviews Drug Discovery volume 10, pages 717718 (2011) | Download Citation

Drugs that block Janus kinases are showing promise in diseases ranging from myelofibrosis to rheumatoid arthritis, but with the leading agent in line for approval questions remain about their optimal selectivity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Elie Dolgin in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing